How to buy DexCom shares

Own DexCom shares in just a few minutes.

Picture not described

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

DexCom, Inc (DXCM) is a leading diagnostics & research business with stocks listed in the US. It opened the day at US$411.91 after a previous close of US$412.45. During the day the price has varied from a low of USD411.1217 to a high of USD419.19. The latest price was USD418.29 (25 minute delay). DexCom is listed on the NASDAQ. All prices are listed in US Dollars.

How to buy shares in DexCom

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for DexCom. Find the share by name or ticker symbol: DXCM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DexCom reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$382.91, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of DexCom, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of DexCom. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

DexCom share price

Use our graph to track the performance of DXCM stocks over time.

DexCom shares at a glance

Information last updated 2021-06-18.
OpenUS$411.91
HighUS$419.19
LowUS$411.1217
CloseUS$418.29
Previous closeUS$412.45
Change US$5.84
Change % 1.4159%
Volume 1,004,083
Information last updated 2021-06-17.
52-week rangeUS$305.63 - US$456.23
50-day moving average US$368.5189
200-day moving average US$371.4171
Target priceUS$476.3
PE ratio 77.5697
Dividend yield N/A (0%)
Earnings per share (TTM) US$5.205

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro (US, EU stock trading)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
Global shares, US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy DexCom stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

DexCom price performance over time

Historical closes compared with the last close of $418.29

1 month (2021-05-21) 22.27%
3 months (2021-03-19) 21.37%
6 months (2020-12-18) 16.66%
1 year (2020-06-19) 2.18%
2 years (2019-06-20) 168.72%
3 years (2018-06-20) 315.59%
5 years (2016-06-20) 441.55%

Is DexCom under- or over-valued?

Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

DexCom's P/E ratio

DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 78x. In other words, DexCom shares trade at around 78x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

DexCom's PEG ratio

DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 11.7433. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

DexCom's EBITDA

DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$374.4 million.

The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.

DexCom financials

Revenue TTM US$2 billion
Operating margin TTM 15.39%
Gross profit TTM US$1.3 billion
Return on assets TTM 5.7%
Return on equity TTM 36.23%
Profit margin 25.36%
Book value 19.681
Market capitalisation US$39 billion

TTM: trailing 12 months

Shorting DexCom shares

There are currently 3.7 million DexCom shares held short by investors – that's known as DexCom's "short interest". This figure is 1.6% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting DexCom shares can be evaluated.

DexCom's "short interest ratio" (SIR)

DexCom's "short interest ratio" (SIR) is the quantity of DexCom shares currently shorted divided by the average quantity of DexCom shares traded daily (recently around 950795.87628866). DexCom's SIR currently stands at 3.88. In other words for every 100,000 DexCom shares traded daily on the market, roughly 3880 shares are currently held short.

However DexCom's short interest can also be evaluated against the total number of DexCom shares, or, against the total number of tradable DexCom shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DexCom's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DexCom shares in existence, roughly 40 shares are currently held short) or 0.0384% of the tradable shares (for every 100,000 tradable DexCom shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DexCom.

Find out more about how you can short DexCom stock.

DexCom's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

DexCom's total ESG risk score

Total ESG risk: 29.18

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

DexCom's environmental score

Environmental score: 10.43/100

DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

DexCom's social score

Social score: 17.04/100

DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

DexCom's governance score

Governance score: 13.2/100

DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

DexCom's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

DexCom, Inc was last rated for ESG on: 2019-01-01.

Total ESG score 29.18
Total ESG percentile 50.12
Environmental score 10.43
Environmental score percentile 6
Social score 17.04
Social score percentile 6
Governance score 13.2
Governance score percentile 6
Level of controversy 2

DexCom share dividends

We're not expecting DexCom to pay a dividend over the next 12 months.

DexCom share price volatility

Over the last 12 months, DexCom's shares have ranged in value from as little as US$305.63 up to US$456.23. A popular way to gauge a stock's volatility is its "beta".

DXCM.US volatility(beta: 0.75)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 0.7511. This would suggest that DexCom's shares are less volatile than average (for this exchange).

DexCom overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform